1
|
Delic S, Mijac V, Gajic I, Kekic D, Ranin L, Jegorovic B, Culic D, Cirkovic V, Siljic M, Stanojevic M, Paragi M, Markovic M, Opavski N. A Laboratory-Based Surveillance Study of Invasive Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae Diseases in a Serbian Pediatric Population-Implications for Vaccination. Diagnostics (Basel) 2021; 11:diagnostics11061059. [PMID: 34207530 PMCID: PMC8228891 DOI: 10.3390/diagnostics11061059] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2021] [Revised: 05/29/2021] [Accepted: 06/04/2021] [Indexed: 11/16/2022] Open
Abstract
The aim of this study was to present the epidemiology of invasive diseases caused by Neisseria meningitidis and Streptococcus pneumoniae in the pre-vaccine period, and Haemophilus influenzae in the post-vaccine period in a pediatric population from Serbia. Among the meningococci, serogroup B dominated (83%), followed by serogroup C (11.3%). High antigenic diversity was found, with fine type P1.5-1,10-4 being the most frequent. Moderate susceptibility to penicillin was common (55%). Within pneumococci, serotypes 19F, 14, 6B, 6A, 18C, 23F, 3, and 7F prevailed, while 19A was rare (3.6%). The coverages of PCV10 and PCV13 were 68% and 84%, respectively. Major sequence types were ST320, ST15, ST273, ST271, and ST81. Non-susceptibility to penicillin (66.7%), cefotaxime (37%), and macrolides (55%) was predominantly detected in vaccine-related serotypes. Among the 11 invasive H. influenzae isolates collected, there were six Hib, three non-type b, and two non-typeable strains (ntHi) that were antibiotic susceptible. These results imply a potential benefit of future Men-B vaccine implementations. For pneumococci, as PCV10 was recently introduced, a significant reduction of morbidity and antibiotic resistance might be expected. The efficiency of Hib vaccination is evident, but a shift towards non-type b and ntHi strains may be anticipated.
Collapse
Affiliation(s)
- Snezana Delic
- Centre for Microbiology, National Reference Laboratory for Meningococcus and Haemophilus, Institute of Public Health, 25101 Sombor, Serbia; (S.D.); (D.C.)
| | - Vera Mijac
- Faculty of Medicine, Institute of Microbiology and Immunology, University of Belgrade, 11000 Belgrade, Serbia; (I.G.); (D.K.); (L.R.); (V.C.); (M.S.); (M.S.); (M.M.); (N.O.)
- National Reference Laboratory for Streptococci, Faculty of Medicine, Institute of Microbiology and Immunology, University of Belgrade, 11000 Belgrade, Serbia
- Correspondence:
| | - Ina Gajic
- Faculty of Medicine, Institute of Microbiology and Immunology, University of Belgrade, 11000 Belgrade, Serbia; (I.G.); (D.K.); (L.R.); (V.C.); (M.S.); (M.S.); (M.M.); (N.O.)
- National Reference Laboratory for Streptococci, Faculty of Medicine, Institute of Microbiology and Immunology, University of Belgrade, 11000 Belgrade, Serbia
| | - Dusan Kekic
- Faculty of Medicine, Institute of Microbiology and Immunology, University of Belgrade, 11000 Belgrade, Serbia; (I.G.); (D.K.); (L.R.); (V.C.); (M.S.); (M.S.); (M.M.); (N.O.)
- National Reference Laboratory for Streptococci, Faculty of Medicine, Institute of Microbiology and Immunology, University of Belgrade, 11000 Belgrade, Serbia
| | - Lazar Ranin
- Faculty of Medicine, Institute of Microbiology and Immunology, University of Belgrade, 11000 Belgrade, Serbia; (I.G.); (D.K.); (L.R.); (V.C.); (M.S.); (M.S.); (M.M.); (N.O.)
- National Reference Laboratory for Streptococci, Faculty of Medicine, Institute of Microbiology and Immunology, University of Belgrade, 11000 Belgrade, Serbia
| | - Boris Jegorovic
- Clinical Centre of Serbia, University Hospital for Infectious and Tropical Diseases, 11000 Belgrade, Serbia;
| | - Davor Culic
- Centre for Microbiology, National Reference Laboratory for Meningococcus and Haemophilus, Institute of Public Health, 25101 Sombor, Serbia; (S.D.); (D.C.)
| | - Valentina Cirkovic
- Faculty of Medicine, Institute of Microbiology and Immunology, University of Belgrade, 11000 Belgrade, Serbia; (I.G.); (D.K.); (L.R.); (V.C.); (M.S.); (M.S.); (M.M.); (N.O.)
| | - Marina Siljic
- Faculty of Medicine, Institute of Microbiology and Immunology, University of Belgrade, 11000 Belgrade, Serbia; (I.G.); (D.K.); (L.R.); (V.C.); (M.S.); (M.S.); (M.M.); (N.O.)
| | - Maja Stanojevic
- Faculty of Medicine, Institute of Microbiology and Immunology, University of Belgrade, 11000 Belgrade, Serbia; (I.G.); (D.K.); (L.R.); (V.C.); (M.S.); (M.S.); (M.M.); (N.O.)
| | - Metka Paragi
- National Laboratory of Health Environment and Food, Department for Public Health Microbiology, 1000 Ljubljana, Slovenia;
| | - Milos Markovic
- Faculty of Medicine, Institute of Microbiology and Immunology, University of Belgrade, 11000 Belgrade, Serbia; (I.G.); (D.K.); (L.R.); (V.C.); (M.S.); (M.S.); (M.M.); (N.O.)
| | - Natasa Opavski
- Faculty of Medicine, Institute of Microbiology and Immunology, University of Belgrade, 11000 Belgrade, Serbia; (I.G.); (D.K.); (L.R.); (V.C.); (M.S.); (M.S.); (M.M.); (N.O.)
- National Reference Laboratory for Streptococci, Faculty of Medicine, Institute of Microbiology and Immunology, University of Belgrade, 11000 Belgrade, Serbia
| |
Collapse
|
2
|
Lourenço J, Daon Y, Gori A, Obolski U. Pneumococcal Competition Modulates Antibiotic Resistance in the Pre-Vaccination Era: A Modelling Study. Vaccines (Basel) 2021; 9:265. [PMID: 33809706 PMCID: PMC8002235 DOI: 10.3390/vaccines9030265] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2021] [Revised: 03/06/2021] [Accepted: 03/09/2021] [Indexed: 11/30/2022] Open
Abstract
The ongoing emergence of antibiotic resistant strains and high frequencies of antibiotic resistance of Streptococcus pneumoniae poses a major public health challenge. How and which ecological and evolutionary mechanisms maintain the coexistence of antibiotic resistant and susceptible strains remains largely an open question. We developed an individual-based, stochastic model expanding on a previous pneumococci modelling framework. We explore how between- and within-host mechanisms of competition can sustain observed levels of resistance to antibiotics in the pre-vaccination era. Our framework considers that within-host competition for co-colonization between resistant and susceptible strains can arise via pre-existing immunity (immunological competition) or intrinsic fitness differences due to resistance costs (ecological competition). We find that beyond stochasticity, population structure or movement, competition at the within-host level can explain observed resistance frequencies. We compare our simulation results to pneumococcal antibiotic resistance data in the European region using approximate Bayesian computation. Our results demonstrate that ecological competition for co-colonization can explain the variation in co-existence of resistant and susceptible pneumococci observed in the pre-vaccination era. Furthermore, we show that within-host pneumococcal competition can facilitate the maintenance of resistance in the pre-vaccination era. Accounting for these competition-related components of pneumococcal dynamics can improve our understanding of drivers for the emergence and maintenance of antibiotic resistance in pneumococci.
Collapse
Affiliation(s)
- José Lourenço
- Department of Zoology, University of Oxford, Oxford OX1 3SZ, UK
| | - Yair Daon
- School of Public Health, Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel;
- Porter School of the Environment and Earth Sciences, Faculty of Exact Sciences, Tel Aviv University, Tel Aviv 69978, Israel
| | - Andrea Gori
- NIHR Global Health Research Unit on Mucosal Pathogens, Division of Infection and Immunity, University College London, London WC1E 6BT, UK;
| | - Uri Obolski
- School of Public Health, Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel;
- Porter School of the Environment and Earth Sciences, Faculty of Exact Sciences, Tel Aviv University, Tel Aviv 69978, Israel
| |
Collapse
|
3
|
Alari A, Cheysson F, Le Fouler L, Lanotte P, Varon E, Opatowski L, Guillemot D, Watier L. Association of Pneumococcal Conjugate Vaccine Coverage With Pneumococcal Meningitis: An Analysis of French Administrative Areas, 2001-2016. Am J Epidemiol 2019; 188:1466-1474. [PMID: 31197305 PMCID: PMC6670069 DOI: 10.1093/aje/kwz071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2018] [Revised: 03/08/2019] [Accepted: 03/12/2019] [Indexed: 11/13/2022] Open
Abstract
Geographic variations of invasive pneumococcal disease incidence and serotype distributions were observed after pneumococcal conjugate vaccine introduction at regional levels and among French administrative areas. The variations could be related to regional vaccine coverage (VC) variations that might have direct consequences for vaccination-policy impact on invasive pneumococcal disease, particularly pneumococcal meningitis (PM) incidence. We assessed vaccine impact from 2001 to 2016 in France by estimating the contribution of regional VC differences to variations of annual local PM incidence. Using a mixed-effect Poisson model, we showed that, despite some variations of VC among administrative areas, vaccine impact on vaccine-serotype PM was homogeneously confirmed among administrative areas. Compared with the prevaccine era, the cumulative VC impact on vaccine serotypes led, in 2016, to PM reductions ranging among regions from 87% (25th percentile) to 91% (75th percentile) for 7-valent pneumococcal conjugate vaccine serotypes and from 58% to 63% for the 6 additional 13-valent pneumococcal conjugate vaccine serotypes. Nonvaccine-serotype PM increases from the prevaccine era ranged among areas from 98% to 127%. By taking into account the cumulative impact of growing VC and VC differences, our analyses confirmed high vaccine impact on vaccine-serotype PM case rates and suggest that VC variations cannot explain PM administrative area differences.
Collapse
Affiliation(s)
- Anna Alari
- Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 1181, Université Versailles St-Quentin-en-Yvelines, Institut Pasteur, Paris, France
- Université Versailles St-Quentin-en-Yvelines, Université Paris-Saclay, Versailles, France
| | - Félix Cheysson
- Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 1181, Université Versailles St-Quentin-en-Yvelines, Institut Pasteur, Paris, France
- Université Paris Sud, Université Paris-Saclay, Le Kremlin Bicêtre, France
| | | | - Philippe Lanotte
- Observatoires Régionaux du Pneumocoque, Service de Bactériologie-Virologie-Hygiène Hospitalière Hôpital Bretonneau, Tours, France
| | - Emmanuelle Varon
- Centre National de Référence des Pneumocoques, Centre Hospitalier Intercommunal, Créteil, France
| | - Lulla Opatowski
- Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 1181, Université Versailles St-Quentin-en-Yvelines, Institut Pasteur, Paris, France
| | - Didier Guillemot
- Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 1181, Université Versailles St-Quentin-en-Yvelines, Institut Pasteur, Paris, France
- Assistance Publique, Hôpitaux de Paris, Hôpital Raymond-Poincaré, Unité Fonctionnelle de Santé Publique, Garches, France
| | - Laurence Watier
- Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 1181, Université Versailles St-Quentin-en-Yvelines, Institut Pasteur, Paris, France
| | | |
Collapse
|
4
|
Abstract
Streptococcus pneumoniae continues to take a heavy toll on childhood mortality and morbidity across the developing world. An estimated 10.6 million invasive pneumococcal diseases (IPDs) occur every year, with nearly 1 million deaths in children under 5 years of age. Introduction of vaccines in the childhood immunisation programme in developed world has brought down the incidence of the disease considerably. However, childhood immunocompromising illnesses including HIV have increased the risk of IPD several folds. There is also a growing concern on the increasing antibiotic resistance among these invasive strains to penicillin, other beta-lactams and macrolides, making treatment difficult and expensive. It is estimated that about 62% of IPD worldwide is caused by the 10 most common serotypes. Although the ranking of individual pneumococcal serotypes causing serious disease varies among nations, the 7-13 serotypes included in pneumococcal conjugate vaccines (PCVs) may prevent 50%-80% of all paediatric pneumococcal diseases globally. The World Health Organization has recommended the use of PCV-10/13 in the national immunisation programmes (NIPs) of developing countries. Four doses of PCV-13 have been recommended by the US Association of Pediatrics and Centers for Disease Control and Prevention, at intervals of each 2 months for the first 6 months and by the 12th to 15th months after birth. This is expected to reduce the morbidity and mortality associated with IPD and simultaneously decrease colonisation with circulating antibiotic-resistant strains in immunized communities. Nevertheless, continued surveillance of antimicrobial resistance in non-vaccine serotypes is necessary to prevent the resurgence of resistance. Other virulence factors which are not serotype specific also need to be studied to overcome the drawbacks of serotype-specific pneumococcal vaccines. PCV-13 was launched during May 2017 under the NIP of five Indian states with the highest pneumococcal diseases in the country and is expected to be rolled out in the other parts of the country in the coming days.
Collapse
Affiliation(s)
- Anand Manoharan
- The CHILDS Trust Medical Research Foundation, Chennai, Tamil Nadu, India
| | - Ranjith Jayaraman
- Department of Clinical Microbiology, Christian Medical College and Hospital, Vellore, Tamil Nadu, India
| |
Collapse
|
5
|
Childhood pneumococcal disease in Africa - A systematic review and meta-analysis of incidence, serotype distribution, and antimicrobial susceptibility. Vaccine 2017; 35:1817-1827. [PMID: 28284682 DOI: 10.1016/j.vaccine.2017.02.045] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2016] [Revised: 01/30/2017] [Accepted: 02/20/2017] [Indexed: 01/28/2023]
Abstract
BACKGROUND Determining the incidence, disease-associated serotypes and antimicrobial susceptibility of invasive pneumococcal disease (IPD) among children in Africa is essential in order to monitor the impact of these infections prior to widespread introduction of the pneumococcal conjugate vaccine (PCV). METHODS To provide updated estimates of the incidence, serotype distribution, and antimicrobial susceptibility profile of Streptococcus pneumoniae causing disease in Africa, we performed a systematic review of articles published from 2000 to 2015 using Ovid Medline and Embase. We included prospective and surveillance studies that applied predefined diagnostic criteria. Meta-analysis for all pooled analyses was based on random-effects models. RESULTS We included 38 studies consisting of 386,880 participants in 21 countries over a total of 350,613 person-years. The pooled incidence of IPD was 62.6 (95% CI 16.9, 226.5) per 100,000 person-years, including meningitis which had a pooled incidence of 24.7 (95% CI 11.9, 51.6) per 100,000 person-years. The pooled prevalence of penicillin susceptibility was 78.1% (95% CI 61.9, 89.2). Cumulatively, PCV10 and PCV13 included 66.9% (95% CI 55.9, 76.7) and 80.6% (95% CI 66.3, 90.5) of IPD serotypes, respectively. CONCLUSIONS Our study provides an integrated and robust summary of incidence data, serotype distribution and antimicrobial susceptibility for S. pneumoniae in children ≤5years of age in Africa prior to widespread introduction of PCV on the continent. The heterogeneity of studies and wide range of incidence rates across the continent indicate that surveillance efforts should be intensified in all regions of Africa to improve the integrity of epidemiologic data, vaccine impact and cost benefit. Although the incidence of IPD in young children in Africa is substantial, currently available conjugate vaccines are estimated to cover the majority of invasive disease-causing pneumococcal serotypes. These data provide a reliable baseline from which to monitor the impact of the broad introduction of PCV.
Collapse
|
6
|
Hocke AC, Suttorp N, Hippenstiel S. Human lung ex vivo infection models. Cell Tissue Res 2016; 367:511-524. [PMID: 27999962 PMCID: PMC7087833 DOI: 10.1007/s00441-016-2546-z] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2016] [Accepted: 11/24/2016] [Indexed: 12/21/2022]
Abstract
Pneumonia is counted among the leading causes of death worldwide. Viruses, bacteria and pathogen-related molecules interact with cells present in the human alveolus by numerous, yet poorly understood ways. Traditional cell culture models little reflect the cellular composition, matrix complexity and three-dimensional architecture of the human lung. Integrative animal models suffer from species differences, which are of particular importance for the investigation of zoonotic lung diseases. The use of cultured ex vivo infected human lung tissue may overcome some of these limitations and complement traditional models. The present review gives an overview of common bacterial lung infections, such as pneumococcal infection and of widely neglected pathogens modeled in ex vivo infected lung tissue. The role of ex vivo infected lung tissue for the investigation of emerging viral zoonosis including influenza A virus and Middle East respiratory syndrome coronavirus is discussed. Finally, further directions for the elaboration of such models are revealed. Overall, the introduced models represent meaningful and robust methods to investigate principles of pathogen-host interaction in original human lung tissue.
Collapse
Affiliation(s)
- Andreas C Hocke
- Department of Internal Medicine/Infectious Diseases and Pulmonary Medicine, Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany
| | - Norbert Suttorp
- Department of Internal Medicine/Infectious Diseases and Pulmonary Medicine, Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany
| | - Stefan Hippenstiel
- Department of Internal Medicine/Infectious Diseases and Pulmonary Medicine, Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany.
| |
Collapse
|
7
|
Nieto PA, Peñaloza HF, Salazar-Echegarai FJ, Castellanos RM, Opazo MC, Venegas L, Padilla O, Kalergis AM, Riedel CA, Bueno SM. Gestational Hypothyroidism Improves the Ability of the Female Offspring to Clear Streptococcus pneumoniae Infection and to Recover From Pneumococcal Pneumonia. Endocrinology 2016; 157:2217-28. [PMID: 27035652 DOI: 10.1210/en.2015-1957] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Maternal thyroid hormones are essential for proper fetal development. A deficit of these hormones during gestation has enduring consequences in the central nervous system of the offspring, including detrimental learning and impaired memory. Few studies have shown that thyroid hormone deficiency has a transient effect in the number of T and B cells in the offspring gestated under hypothyroidism; however, there are no studies showing whether maternal hypothyroidism during gestation impacts the response of the offspring to infections. In this study, we have evaluated whether adult mice gestated in hypothyroid mothers have an altered response to pneumococcal pneumonia. We observed that female mice gestated in hypothyroidism have increased survival rate and less bacterial dissemination to blood and brain after an intranasal challenge with Streptococcus pneumoniae. Further, these mice had higher amounts of inflammatory cells in the lungs and reduced production of cytokines characteristic of sepsis in spleen, blood, and brain at 48 hours after infection. Interestingly, mice gestated in hypothyroid mothers had basally increased vascular permeability in the lungs. These observations suggest that gestational hypothyroidism alters the immune response and the physiology of lungs in the offspring, increasing the resistance to respiratory bacterial infections.
Collapse
Affiliation(s)
- Pamela A Nieto
- Millennium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile (P.A.N., H.F.P., F.J.S.-E., A.M.K., S.A.M.), Santiago, Chile 8331150; Departamento de Morfología, Facultad de Medicina, Universidad Andrés Bello (R.M.C.), Santiago, Chile 8370146; Millennium Institute on Immunology and Immunotherapy, Departamento de Ciencias Biológicas, Facultad de Ciencias Biológicas y Facultad de Medicina, Universidad Andrés Bello (M.C.O., L.V., C.A.R.), Santiago, Chile 8370146; Departamento de Salud Pública, Escuela de Medicina, Pontificia Universidad Católica de Chile (O.P.), Santiago, Chile 8330073; Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche 1064 (A.M.K., S.M.B.), Nantes, France 44093; and Departamento de Endocrinología, Facultad de Medicina, Pontificia Universidad Católica de Chile (A.M.K.), Santiago, Chile 8330074
| | - Hernán F Peñaloza
- Millennium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile (P.A.N., H.F.P., F.J.S.-E., A.M.K., S.A.M.), Santiago, Chile 8331150; Departamento de Morfología, Facultad de Medicina, Universidad Andrés Bello (R.M.C.), Santiago, Chile 8370146; Millennium Institute on Immunology and Immunotherapy, Departamento de Ciencias Biológicas, Facultad de Ciencias Biológicas y Facultad de Medicina, Universidad Andrés Bello (M.C.O., L.V., C.A.R.), Santiago, Chile 8370146; Departamento de Salud Pública, Escuela de Medicina, Pontificia Universidad Católica de Chile (O.P.), Santiago, Chile 8330073; Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche 1064 (A.M.K., S.M.B.), Nantes, France 44093; and Departamento de Endocrinología, Facultad de Medicina, Pontificia Universidad Católica de Chile (A.M.K.), Santiago, Chile 8330074
| | - Francisco J Salazar-Echegarai
- Millennium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile (P.A.N., H.F.P., F.J.S.-E., A.M.K., S.A.M.), Santiago, Chile 8331150; Departamento de Morfología, Facultad de Medicina, Universidad Andrés Bello (R.M.C.), Santiago, Chile 8370146; Millennium Institute on Immunology and Immunotherapy, Departamento de Ciencias Biológicas, Facultad de Ciencias Biológicas y Facultad de Medicina, Universidad Andrés Bello (M.C.O., L.V., C.A.R.), Santiago, Chile 8370146; Departamento de Salud Pública, Escuela de Medicina, Pontificia Universidad Católica de Chile (O.P.), Santiago, Chile 8330073; Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche 1064 (A.M.K., S.M.B.), Nantes, France 44093; and Departamento de Endocrinología, Facultad de Medicina, Pontificia Universidad Católica de Chile (A.M.K.), Santiago, Chile 8330074
| | - Raquel M Castellanos
- Millennium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile (P.A.N., H.F.P., F.J.S.-E., A.M.K., S.A.M.), Santiago, Chile 8331150; Departamento de Morfología, Facultad de Medicina, Universidad Andrés Bello (R.M.C.), Santiago, Chile 8370146; Millennium Institute on Immunology and Immunotherapy, Departamento de Ciencias Biológicas, Facultad de Ciencias Biológicas y Facultad de Medicina, Universidad Andrés Bello (M.C.O., L.V., C.A.R.), Santiago, Chile 8370146; Departamento de Salud Pública, Escuela de Medicina, Pontificia Universidad Católica de Chile (O.P.), Santiago, Chile 8330073; Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche 1064 (A.M.K., S.M.B.), Nantes, France 44093; and Departamento de Endocrinología, Facultad de Medicina, Pontificia Universidad Católica de Chile (A.M.K.), Santiago, Chile 8330074
| | - Maria Cecilia Opazo
- Millennium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile (P.A.N., H.F.P., F.J.S.-E., A.M.K., S.A.M.), Santiago, Chile 8331150; Departamento de Morfología, Facultad de Medicina, Universidad Andrés Bello (R.M.C.), Santiago, Chile 8370146; Millennium Institute on Immunology and Immunotherapy, Departamento de Ciencias Biológicas, Facultad de Ciencias Biológicas y Facultad de Medicina, Universidad Andrés Bello (M.C.O., L.V., C.A.R.), Santiago, Chile 8370146; Departamento de Salud Pública, Escuela de Medicina, Pontificia Universidad Católica de Chile (O.P.), Santiago, Chile 8330073; Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche 1064 (A.M.K., S.M.B.), Nantes, France 44093; and Departamento de Endocrinología, Facultad de Medicina, Pontificia Universidad Católica de Chile (A.M.K.), Santiago, Chile 8330074
| | - Luis Venegas
- Millennium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile (P.A.N., H.F.P., F.J.S.-E., A.M.K., S.A.M.), Santiago, Chile 8331150; Departamento de Morfología, Facultad de Medicina, Universidad Andrés Bello (R.M.C.), Santiago, Chile 8370146; Millennium Institute on Immunology and Immunotherapy, Departamento de Ciencias Biológicas, Facultad de Ciencias Biológicas y Facultad de Medicina, Universidad Andrés Bello (M.C.O., L.V., C.A.R.), Santiago, Chile 8370146; Departamento de Salud Pública, Escuela de Medicina, Pontificia Universidad Católica de Chile (O.P.), Santiago, Chile 8330073; Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche 1064 (A.M.K., S.M.B.), Nantes, France 44093; and Departamento de Endocrinología, Facultad de Medicina, Pontificia Universidad Católica de Chile (A.M.K.), Santiago, Chile 8330074
| | - Oslando Padilla
- Millennium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile (P.A.N., H.F.P., F.J.S.-E., A.M.K., S.A.M.), Santiago, Chile 8331150; Departamento de Morfología, Facultad de Medicina, Universidad Andrés Bello (R.M.C.), Santiago, Chile 8370146; Millennium Institute on Immunology and Immunotherapy, Departamento de Ciencias Biológicas, Facultad de Ciencias Biológicas y Facultad de Medicina, Universidad Andrés Bello (M.C.O., L.V., C.A.R.), Santiago, Chile 8370146; Departamento de Salud Pública, Escuela de Medicina, Pontificia Universidad Católica de Chile (O.P.), Santiago, Chile 8330073; Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche 1064 (A.M.K., S.M.B.), Nantes, France 44093; and Departamento de Endocrinología, Facultad de Medicina, Pontificia Universidad Católica de Chile (A.M.K.), Santiago, Chile 8330074
| | - Alexis M Kalergis
- Millennium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile (P.A.N., H.F.P., F.J.S.-E., A.M.K., S.A.M.), Santiago, Chile 8331150; Departamento de Morfología, Facultad de Medicina, Universidad Andrés Bello (R.M.C.), Santiago, Chile 8370146; Millennium Institute on Immunology and Immunotherapy, Departamento de Ciencias Biológicas, Facultad de Ciencias Biológicas y Facultad de Medicina, Universidad Andrés Bello (M.C.O., L.V., C.A.R.), Santiago, Chile 8370146; Departamento de Salud Pública, Escuela de Medicina, Pontificia Universidad Católica de Chile (O.P.), Santiago, Chile 8330073; Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche 1064 (A.M.K., S.M.B.), Nantes, France 44093; and Departamento de Endocrinología, Facultad de Medicina, Pontificia Universidad Católica de Chile (A.M.K.), Santiago, Chile 8330074
| | - Claudia A Riedel
- Millennium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile (P.A.N., H.F.P., F.J.S.-E., A.M.K., S.A.M.), Santiago, Chile 8331150; Departamento de Morfología, Facultad de Medicina, Universidad Andrés Bello (R.M.C.), Santiago, Chile 8370146; Millennium Institute on Immunology and Immunotherapy, Departamento de Ciencias Biológicas, Facultad de Ciencias Biológicas y Facultad de Medicina, Universidad Andrés Bello (M.C.O., L.V., C.A.R.), Santiago, Chile 8370146; Departamento de Salud Pública, Escuela de Medicina, Pontificia Universidad Católica de Chile (O.P.), Santiago, Chile 8330073; Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche 1064 (A.M.K., S.M.B.), Nantes, France 44093; and Departamento de Endocrinología, Facultad de Medicina, Pontificia Universidad Católica de Chile (A.M.K.), Santiago, Chile 8330074
| | - Susan M Bueno
- Millennium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile (P.A.N., H.F.P., F.J.S.-E., A.M.K., S.A.M.), Santiago, Chile 8331150; Departamento de Morfología, Facultad de Medicina, Universidad Andrés Bello (R.M.C.), Santiago, Chile 8370146; Millennium Institute on Immunology and Immunotherapy, Departamento de Ciencias Biológicas, Facultad de Ciencias Biológicas y Facultad de Medicina, Universidad Andrés Bello (M.C.O., L.V., C.A.R.), Santiago, Chile 8370146; Departamento de Salud Pública, Escuela de Medicina, Pontificia Universidad Católica de Chile (O.P.), Santiago, Chile 8330073; Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche 1064 (A.M.K., S.M.B.), Nantes, France 44093; and Departamento de Endocrinología, Facultad de Medicina, Pontificia Universidad Católica de Chile (A.M.K.), Santiago, Chile 8330074
| |
Collapse
|
8
|
Soto-Noguerón A, Carnalla-Barajas MN, Solórzano-Santos F, Arrendondo-García JL, Arzate-Barbosa P, Tinoco-Favila JC, Anzurez-Gutiérrez A, Echániz-Aviles G. Streptococcus pneumoniae as cause of infection in infants less than 60 days of age: serotypes and antimicrobial susceptibility. Int J Infect Dis 2015; 42:69-73. [PMID: 26673859 DOI: 10.1016/j.ijid.2015.12.001] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2015] [Revised: 11/26/2015] [Accepted: 12/02/2015] [Indexed: 11/19/2022] Open
Abstract
OBJECTIVE The aim of this study was to determine the distribution of serotypes and the antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates causing invasive and non-invasive disease in children aged ≤60 days in hospitals in Mexico. METHODS A 15-year retrospective study was conducted for the period 2000 to 2014. Pneumococcal clinical isolates were serotyped by Quellung reaction, and antimicrobial susceptibility testing was performed with the broth microdilution method. RESULTS A total of 126 pneumococcal isolates were collected. Pneumonia was the most frequent diagnosis (40.5%), followed by meningitis (29.4%), septicemia (16.7%), and other clinical entities, including otitis media and conjunctivitis (13.5%). The most frequent serotypes before the introduction of heptavalent pneumococcal conjugate vaccine (PCV7) were 19F, 23F, 7F, and 35B. Serotypes 3, 6A, 10A, 12F, and 15A/B increased after the introduction of PCV7. Serotype 19A was isolated most frequently in the pneumonia and meningitis cases only after the introduction of PCV7, and it displayed a high resistance to penicillin. CONCLUSIONS Although the number of infections in infants aged ≤60 days was low, such infections were not unusual events. New vaccination strategies should be evaluated to limit the risks in this age group.
Collapse
Affiliation(s)
- Araceli Soto-Noguerón
- Instituto Nacional de Salud Pública, Avenida Universidad 655, Cuernavaca, Morelos 62100, Mexico
| | | | - Fortino Solórzano-Santos
- Unidad Médica de Alta Especialidad, Hospital de Pediatría Centro Médico Nacional SXXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico
| | | | | | | | | | - Gabriela Echániz-Aviles
- Instituto Nacional de Salud Pública, Avenida Universidad 655, Cuernavaca, Morelos 62100, Mexico.
| |
Collapse
|
9
|
Decreased Incidence of Respiratory Infections in Children After Vaccination with Ten-valent Pneumococcal Vaccine. Pediatr Infect Dis J 2015; 34:1385-90. [PMID: 26780024 DOI: 10.1097/inf.0000000000000899] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
INTRODUCTION Respiratory tract infections (RTIs) and antibiotic usage are common in children, increasing the risk of antibacterial resistance. The introduction of protein-conjugated pneumococcal vaccines has led to reduction in pneumococcal infections. In 2011, pneumococcal protein-conjugated vaccine-10 was introduced into the national childhood vaccination in Iceland, a population not earlier vaccinated against pneumococcus, with 95% vaccine uptake in the first year. The aim of the study was to evaluate the number of children visiting the Children's Hospital Iceland for RTIs before and after the introduction of the vaccine. METHODS Admissions and visits to the Children's Hospital because of RTIs were recorded, and children aged 3 months to 2 years in the nonvaccine eligible cohort (born 2008-2010) were compared with the vaccine eligible cohort (born in 2011). Statistical analysis was done using large sample Z test and incidence rate ratios (IRRs) were calculated. RESULTS A significant reduction in incidence rate was found when comparing the nonvaccine eligible cohort with the vaccine eligible cohort, both for acute otitis media (AOM) (IRR: 0.76; 95% confidence interval: 0.67-0.87; P < 0.0001) and for pneumonia (IRR: 0.77; 95% confidence interval: 0.64-0.95; P < 0.01). CONCLUSION A significant reduction in hospital visits because of AOM and pneumonia in children vaccinated with pneumococcal protein-conjugated vaccine-10 was established. The abrupt and significant reduction of AOM is unusually clear. This reduction was noted very early after initiation of the vaccination.
Collapse
|
10
|
Lowbridge C, McIntyre PB, Gilmour R, Chiu C, Seale H, Ferson MJ, Gilbert GL. Long term population impact of seven-valent pneumococcal conjugate vaccine with a "3+0″ schedule-How do "2+1″ and "3+1″ schedules compare? Vaccine 2015; 33:3234-41. [PMID: 25952557 DOI: 10.1016/j.vaccine.2015.04.079] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2014] [Revised: 04/01/2015] [Accepted: 04/22/2015] [Indexed: 10/23/2022]
Abstract
INTRODUCTION Significant reductions in invasive pneumococcal disease (IPD) following 7-valent pneumococcal conjugate vaccine (7vPCV) are well documented, but population-level data comparing different schedules are sparse. We compared data from long-term stable surveillance in one Australian region (3 primary doses (3+0) schedule) with similar data from England and Wales (2+1 schedule) and the United States (3+1 schedule). METHODS Incidence rate ratios (IRRs) for all, vaccine type, and non-vaccine type IPD were calculated by age-group, using comparable case definitions and time periods post 7vPCV introduction. RESULTS At baseline, the % of IPD due to 7vPCV serotypes (VT) disease in children <5 years was 88% in Greater Sydney (GS), 83% in the United States (US), and 74% in England and Wales (E&W). IRR for VT IPD <5 years in GS was 0.05 (0.02-0.09), for ≥65 years was 0.15 (0.12-0.19) and for all ages 0.12 (0.10-0.13). In the US, IRR for VT IPD was lower in each age group, and for all ages the 95% CI of the IRR (0.06 (0.05-0.07)), did not overlap with GS or E&W (0.14 (0.11-0.18)). In contrast, the IRR for IPD due to any serotype did not differ between sites for any age group or overall. CONCLUSIONS Differences in direct and indirect reductions in VT IPD with a "3+0″ 7vPCV schedule versus "2+1″ or "3+1″ were small. All 3 countries moved to 13vPCV by 2011; data post 13vPCV will be important to assess IPD impact using more similar baseline incidence and comparison periods.
Collapse
Affiliation(s)
- Christopher Lowbridge
- Public Health Officer Training Program, New South Wales Ministry of Health, Sydney, NSW, Australia; School of Public Health and Community Medicine, University of New South Wales, Sydney, NSW, Australia.
| | - Peter B McIntyre
- National Centre for Immunisation Research and Surveillance, Children's Hospital, Westmead, Sydney, NSW, Australia; Discipline of Paediatrics and Child Health and School of Public Health, University of Sydney, Children's Hospital, Westmead, Sydney, NSW, Australia.
| | - Robin Gilmour
- Health Protection New South Wales, Sydney, Australia.
| | - Clayton Chiu
- National Centre for Immunisation Research and Surveillance, Children's Hospital, Westmead, Sydney, NSW, Australia.
| | - Holly Seale
- School of Public Health and Community Medicine, University of New South Wales, Sydney, NSW, Australia.
| | - Mark J Ferson
- School of Public Health and Community Medicine, University of New South Wales, Sydney, NSW, Australia.
| | - Gwendolyn L Gilbert
- Centre for Infectious Diseases and Microbiology-Public Health, Sydney, NSW, Australia.
| |
Collapse
|
11
|
Weiss S, Falkenhorst G, van der Linden M, Imohl M, von Kries R. Impact of 10- and 13-valent pneumococcal conjugate vaccines on incidence of invasive pneumococcal disease in children aged under 16 years in Germany, 2009 to 2012. ACTA ACUST UNITED AC 2015; 20:21057. [PMID: 25788255 DOI: 10.2807/1560-7917.es2015.20.10.21057] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
We assessed the impact of 10-valent and 13-valent pneumococcal vaccines (PCV10 and PCV13), which were introduced in Germany in 2009, on the incidence of meningitis and non-meningitis invasive pneumococcal disease (IPD) in children aged under 16 years in a population previously vaccinated with a seven-valent vaccine (PCV7). Surveillance of IPD (isolation of Streptococcus pneumonia from a normally sterile body site) is based on data from two independent reporting sources: hospitals and laboratories. IPD incidence was estimated by capture-recapture analysis. Incidence rate ratios (IRRs) were calculated for 2009 and 2012, thus comparing pre- and post-PCV10 and PCV13 data. IPD incidence caused by serotypes included in PCV13 decreased in all age and diagnosis groups. A rise in non-vaccine serotype incidence was seen only in children aged under two years. The overall impact varied by age group and infection site: for meningitis IPD in children aged under 2, 2-4 and 5-15 years, incidence changed by 3% (95% CI: -31 to 52), -60% (95% CI: -81 to -17) and -9% (95% CI: -46 to 53), respectively. A more pronounced incidence reduction was observed for non-meningitis IPD: -30% (95% CI: -46 to -7), -39% (95% CI: -54 to -20) and -83% (95% CI: -89 to -73) in children aged under 2, 2-4 and 5-15 years, respectively. A higher tropism of the additional serotypes for non-meningitis IPD may be a potential explanation. The heterogeneous findings emphasise the need for rigorous surveillance
Collapse
Affiliation(s)
- S Weiss
- Ludwig-Maximilians-University of Munich, Institute of Social Paediatrics and Adolescent Medicine, Munich, Germany
| | | | | | | | | |
Collapse
|
12
|
Invasive pneumococcal diseases in children and adolescents--a single centre experience. BMC Res Notes 2014; 7:145. [PMID: 24625087 PMCID: PMC3984689 DOI: 10.1186/1756-0500-7-145] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2013] [Accepted: 03/06/2014] [Indexed: 12/17/2022] Open
Abstract
Background S. pneumoniae is a major cause of meningitis, pneumonia and sepsis in children. In 2006 universal pneumococcal vaccination was recommended in Germany for all children up to their second birthday. We have compared the prevalence and outcome of IPD at a single hospital before and after the introduction of vaccination. Findings 55 cases of IPD were identified over an 11 year period. Almost half of the patients were younger than 2 years of age. Most of the children were affected by pneumonia. The second highest incidence seen was for meningitis and sepsis. 17 patients exhibited additional complications. Significant pre-existing and predisposing disorders, such as IRAK 4 defect, ALPS or SLE were identified in 4 patients. Complete recovery was seen in 78% of affected children; 11% had a fatal outcome and 11% suffered from long term complications. Only 31% overall had been vaccinated. The most common serotype was 14. Serotypes not covered by any of the current vaccines were also found. Antibiotic treatment commenced with cephalosporins in over 90%. Conclusion Frequency of IPD in our hospital did not decrease after initiation of the pneumococcal vaccination. This might be due to vaccinations not being administered satisfactorily as well as to poor education about the need of the vaccination. Pre-existing diseases must be monitored and treated accordingly and rare deficiencies taken into account when IPD takes a foudroyant course. In addition, antibiotic stewardship has been initiated at this hospital centre as a consequence of the high cephalosporin use detected in this study.
Collapse
|
13
|
Serotypes and antibiotic resistance of non-invasive Streptococcus pneumoniae circulating in pediatric hospitals in Moscow, Russia. Int J Infect Dis 2014; 20:58-62. [PMID: 24462930 DOI: 10.1016/j.ijid.2013.11.005] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2013] [Revised: 10/29/2013] [Accepted: 11/14/2013] [Indexed: 11/23/2022] Open
Abstract
BACKGROUND Pneumococcal infections remain a major medical problem associated with high morbidity and mortality. Moreover, the resistance of Streptococcus pneumoniae to conventional antibiotics is constantly growing. The implementation of pneumococcal conjugate vaccines (PCVs) in the last decade has dramatically reduced the incidence of the vaccine type-associated invasive pneumococcal diseases in many countries. However, information on the seroepidemiology of S. pneumoniae in Russia is limited. METHODS We report the results of serotyping and antibiotic susceptibility testing performed on 863 non-invasive pneumococcal isolates collected prospectively in 2009-2013 from children (median age 3.5 years) who sought medical care at five pediatric hospitals in Moscow. The isolates were recovered from the nasopharynx (71.2%), middle ear fluid (14.3%), and lower respiratory tract specimens (13.6%). RESULTS In total, we identified 45 different serotypes. The six leading serotypes (prevalence >5%) included 19F (21.7%), 6B (12.8%), 23F (10.1%), 14 (9.0%), 6A (8.4%), and 3 (7.5%). Serotype 19A isolates had a prevalence of 2.3%. The proportion of PCV-13 serotypes was 78%; the coverage by PCV-7 was 58.2% and was similar to that of PCV-10 (59.8%). The rate of multidrug-resistant pneumococci (i.e., resistant to ≥3 antimicrobials) was 22%. The majority of the multidrug-resistant isolates were serotype 6B, 14, 19A, and 19F. Penicillin non-susceptibility was displayed by 28% of the isolates. The resistance rate to erythromycin was 26%. Among the examined erythromycin-resistant strains, 54% had the erm(B) gene and 13% had the mef gene as a single resistance determinant, whereas both determinants were found in 31% of these strains. CONCLUSIONS Our data predict a good coverage of the circulating S. pneumoniae by the PCVs and could be useful for evaluating the serotype distribution in support of the introduction of PCV in Russia. In addition, the antimicrobial resistance rate of S. pneumoniae in Russia is substantial, and the emergence of pneumococcal strains with a dual macrolide resistance mechanism is alarming.
Collapse
|
14
|
Rozenbaum MH, Boersma C, Postma MJ, Hak E. Observed differences in invasive pneumococcal disease epidemiology after routine infant vaccination. Expert Rev Vaccines 2014; 10:187-99. [DOI: 10.1586/erv.10.163] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
15
|
Rose M, Zielen S. Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe. Expert Rev Vaccines 2014; 8:1351-64. [PMID: 19803758 DOI: 10.1586/erv.09.78] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Markus Rose
- Children's Hospital, Goethe University, Theodor Stern Kai 7, 60590 Frankfurt, Germany.
| | | |
Collapse
|
16
|
Complete Genome Sequence of Streptococcus pneumoniae Strain A026, a Clinical Multidrug-Resistant Isolate Carrying Tn2010. GENOME ANNOUNCEMENTS 2013; 1:1/6/e01034-13. [PMID: 24336372 PMCID: PMC3861425 DOI: 10.1128/genomea.01034-13] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Streptococcus pneumoniae is a primary cause of bacterial infection in humans. Here, we present the complete genome sequence of S. pneumoniae strain A026, which is a multidrug-resistant strain isolated from cerebrospinal fluid.
Collapse
|
17
|
O’Grady KAF, Chang AB, Grimwood K. Vaccines for children and adults with chronic lung disease: efficacy against acute exacerbations. Expert Rev Respir Med 2013; 8:43-55. [DOI: 10.1586/17476348.2014.852960] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
18
|
Nicoletti MC, Bertini JR, Tanizaki MM, Zangirolami TC, Gonçalves VM, Horta ACL, Giordano RC. On-line prediction of the feeding phase in high-cell density cultivation of rE. coli using constructive neural networks. COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE 2013; 111:228-248. [PMID: 23566708 DOI: 10.1016/j.cmpb.2013.03.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/24/2011] [Revised: 12/18/2012] [Accepted: 03/11/2013] [Indexed: 06/02/2023]
Abstract
Streptococcus pneumoniae (pneumococcus) is a bacterium responsible for a wide spectrum of illnesses. The surface of the bacterium consists of three distinctive membranes: plasmatic, cellular and the polysaccharide (PS) capsule. PS capsules may mediate several biological processes, particularly invasive infections of human beings. Prevention against pneumococcal related illnesses can be provided by vaccines. There is a sound investment worldwide in the investigation of a proteic antigen as a possible alternative to pneumococcal vaccines based exclusively on PS. A few proteins which are part of the membrane of the pneumococcus seem to have antigen potential to be part of a vaccine, particularly the PspA. A vital aspect in the production of the intended conjugate pneumococcal vaccine is the efficient production (in industrial scale) of both, the chosen PS serotypes as well as the PspA protein. Growing recombinant Escherichia coli (rE. coli) in high-cell density cultures (HCDC) under a fed-batch regime requires a refined continuous control over various process variables where the on-line prediction of the feeding phase is of particular relevance and one of the focuses of this paper. The viability of an on-line monitoring software system, based on constructive neural networks (CoNN), for automatically detecting the time to start the fed-phase of a HCDC of rE. coli that contains a plasmid used for PspA expression is investigated. The paper describes the data and methodology used for training five different types of CoNNs, four of them suitable for classification tasks and one suitable for regression tasks, aiming at comparatively investigate both approaches. Results of software simulations implementing five CoNN algorithms as well as conventional neural networks (FFNN), decision trees (DT) and support vector machines (SVM) are also presented and discussed. A modified CasCor algorithm, implementing a data softening process, has shown to be an efficient candidate to be part of an on-line HCDC monitoring system for detecting the feeding phase of the HCDC process.
Collapse
Affiliation(s)
- M C Nicoletti
- Depto. de Computação, UFSCar, S. Carlos, SP, Brazil.
| | | | | | | | | | | | | |
Collapse
|
19
|
Luthander J, Bennet R, Giske CG, Nilsson A, Eriksson M. Age and risk factors influence the microbial aetiology of bloodstream infection in children. Acta Paediatr 2013; 102:182-6. [PMID: 23121094 DOI: 10.1111/apa.12077] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/18/2012] [Revised: 08/30/2012] [Accepted: 10/30/2012] [Indexed: 11/30/2022]
Abstract
AIM To study the aetiology of bloodstream infections (BSI) in children 0-17 years, the influence of age and underlying co-morbidity on BSI rate, distribution of pathogens and outcome; and to provide data on antimicrobial susceptibility patterns. METHODS A retrospective population-based study. Data on blood cultures were collected at yearly intervals during 1998-2008. Information about risk factors, focal infection and outcome was retrieved from the patient charts. RESULTS We identified 1097 BSI. The incidence of BSI was 0.4/1000. The age-specific incidence was 2.3/1000 in neonates (0-28 days old) and 0.2/1000 in the age group 6-17 years. Staphylococcus aureus was the most common pathogen. The number of species causing BSI in previously healthy children was lower compared with children with co-morbidity. Most children requiring intensive care had a serious underlying illness. Antimicrobial resistance was rare and did not influence outcome. The case-fatality rate was 14.4% in neonates, 5.4% in children with co-morbidity and 1.7% in previously healthy children. CONCLUSION Mortality from BSI is low, and a limited spectrum of pathogens is isolated from previously healthy children compared with children with co-morbidity. When choosing empirical therapy for suspected BSI, age and presence of risk factors should be taken into account.
Collapse
Affiliation(s)
| | - Rutger Bennet
- Pediatric Infectious Diseases Unit at the Pediatric Emergency Department; Astrid Lindgren's Children Hospital; Stockholm; Sweden
| | - Christian G Giske
- Clinical Microbiology, Department of Microbiology, Tumor and Cell Biology (MTC); Karolinska University Hospital; Karolinska Institutet; Stockholm; Sweden
| | | | - Margareta Eriksson
- Pediatric Infectious Diseases Unit at the Pediatric Emergency Department; Astrid Lindgren's Children Hospital; Stockholm; Sweden
| |
Collapse
|
20
|
Ladhani SN, Andrews NJ, Waight P, Borrow R, Slack MPE, Miller E. Impact of the 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in infants younger than 90 days in England and wales. Clin Infect Dis 2012; 56:633-40. [PMID: 23175560 DOI: 10.1093/cid/cis934] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Streptococcus pneumoniae is an uncommon but well-recognized cause of invasive bacterial disease in young infants. This study aimed to determine the impact of the 7-valent pneumococcal conjugate vaccine (PCV7) on invasive pneumococcal disease (IPD) in infants aged <90 days in England and Wales and describe their clinical characteristics following PCV7 introduction. METHODS Trends in IPD among infants aged <90 days during 1998-1999 through 2009-2010 were analyzed using enhanced national surveillance data. Following PCV7 introduction, clinical information was also obtained for IPD cases in the birth cohorts eligible for vaccination. RESULTS Prior to PCV7 introduction, IPD incidence in infants aged <90 days was 13.0 (95% confidence interval [CI], 12.0-14.0) per 100 000 live births and PCV7 serotypes accounted for 44% (154/349) of serotyped isolates. PCV7 introduction resulted in 83% (95% CI, 66%-91%, P < .001) reduction in PCV7 IPD and a declining trend in overall IPD by 2009-2010. Of the 256 cases diagnosed after PCV7 introduction, 23% (n = 60) had been born before 37 weeks' gestation. A third of cases (84/256, 33%) developed IPD in the first 48 hours of life, where 42% (35/84) were premature. Meningitis was diagnosed in 94 infants (37%) and its prevalence increased with age. Case fatality was 7% (18/256) and was higher for meningitis than nonmeningitis cases (adjusted odds ratio, 3.8 [95% CI, 1.2-12.0], P = .024). CONCLUSIONS Young infants have benefited from PCV7 through indirect (herd) protection. Given that a third of cases occurred within 48 hours of birth, further studies should focus on risk factors for IPD in pregnancy and strategies to prevent mother-to-child transmission.
Collapse
Affiliation(s)
- Shamez N Ladhani
- Health Protection Services Colindale, Health Protection Agency, Manchester Royal Infirmary, Manchester, United Kingdom.
| | | | | | | | | | | |
Collapse
|
21
|
Abstract
Three bacteria--Haemophilus influenzae, Streptococcus pneumoniae, and Neisseria meningitidis--account for most acute bacterial meningitis. Measurement of the effect of protein-polysaccharide conjugate vaccines is most reliable for H influenzae meningitis because one serotype and one age group account for more than 90% of cases and the incidence has been best measured in high-income countries where these vaccines have been used longest. Pneumococcal and meningococcal meningitis are caused by diverse serotypes and have a wide age distribution; measurement of their incidence is complicated by epidemics and scarcity of surveillance, especially in low-income countries. Near elimination of H influenzae meningitis has been documented after vaccine introduction. Despite greater than 90% reductions in disease attributable to vaccine serotypes, all-age pneumococcal meningitis has decreased by around 25%, with little data from low-income settings. Near elimination of serogroup C meningococcal meningitis has been documented in several high-income countries, boding well for the effect of a new serogroup A meningococcal conjugate vaccine in the African meningitis belt.
Collapse
Affiliation(s)
- Peter B McIntyre
- National Centre for Immunisation Research and Surveillance of Vaccine-Preventable Diseases, The Children's Hospital at Westmead and the University of Sydney, Sydney, NSW, Australia.
| | | | | | | |
Collapse
|
22
|
Factors influencing neurological outcome of children with bacterial meningitis at the emergency department. Eur J Pediatr 2012; 171:1365-71. [PMID: 22527566 DOI: 10.1007/s00431-012-1733-5] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/10/2012] [Accepted: 03/28/2012] [Indexed: 10/28/2022]
Abstract
We performed a cohort study of children who survived bacterial meningitis after the neonatal period at a single pediatric center in France over a 10-year period (1995-2004) to identify predictors of death and long-term neurological deficits in children with bacterial meningitis. We performed multivariate regression to determine independent predictors of death and neurologic deficits. We identified 101 children with bacterial meningitis of which 19 died during initial hospitalization. Need for mechanical ventilation [hazard ratio (HR) 11.5, 95 % confidence interval (CI) 2.4-55.5)] and thrombocytopenia defined as a platelet count <150 × 10(9) per liter (HR 0.6, 95 % CI 0.4-0.9) at presentation were associated with death during initial hospitalization. At final assessment, 42 of the 70 survivors had no neurologic deficits identified; 20 had a single deficit, and eight had multiple deficits. A delay in initiation of antibiotics (HR 1.3, 95 % CI 1.1-1.7) and hydrocephalus on computed tomographic scan (HR 2.6, 95 % CI 1.1-6.0) were associated with having one or more long-term neurologic deficits. Identification of children at risk of death or long-term neurologic sequelae may allow therapeutic interventions to be directed to children at the highest risk.
Collapse
|
23
|
van der Linden M, Weiß S, Falkenhorst G, Siedler A, Imöhl M, von Kries R. Four years of universal pneumococcal conjugate infant vaccination in Germany: impact on incidence of invasive pneumococcal disease and serotype distribution in children. Vaccine 2012; 30:5880-5. [PMID: 22771186 DOI: 10.1016/j.vaccine.2012.06.068] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2012] [Revised: 06/18/2012] [Accepted: 06/21/2012] [Indexed: 11/17/2022]
Abstract
INTRODUCTION Vaccination with pneumococcal conjugate vaccine (PCV) for all children <2 years was recommended in Germany in July 2006. Initially PCV7 was exclusively used; PCV10 became available from April 2009 and PCV7 was replaced by PCV13 in December 2009. OBJECTIVE To compare the incidence and serotype distribution of invasive pneumococcal disease (IPD) for pneumococcal meningitis and non-meningitis IPD in children from 2007 to 2010 with reference to the pre-vaccination period from 1997 to 2001. METHODS Nationwide surveillance of IPD for children <16 years in Germany was based on two independent reporting sources: active surveillance in paediatric hospitals and passive web-based surveillance through microbiological laboratories. Serotyping was performed using the Neufeld Quellung reaction. CASE DEFINITION isolation of Streptococcus pneumoniae from a normally sterile body site. IPD incidence was estimated by capture-recapture analysis. Rate ratios comparing post- to pre-vaccination incidence were calculated as well as PCV7 and non-PCV7 serotype specific incidences. RESULTS While PCV7 incidence decreased by 88% (95%CI: 83 to 91) in children <16 years both in pneumococcal meningitis and non-meningitis IPD, an increase in Non-PCV7 serotypes was observed which was more pronounced in non-meningitis cases (168%; 95%CI: 140-257) than in pneumoccocal meningitis (65%; 95%CI: 23-123). The changes in incidence after four years were: <16 years: -35% (95%CI: -49 to -19), <2 years: -46% (95%CI: -61 to -27) for pneumococcal meningitis and+11% (95%CI: -4 to +29) and -26% (95%CI: -41 to -7) for non-meningitis IPD respectively. CONCLUSION Infant PCV7 vaccination in Germany prompted a decrease in the incidence of pneumococcal meningitis similar to that observed in England/Wales. In non-meningitis IPD the decrease was smaller and confined to the age group <2 years with no change or an increase in incidence in other age groups pointing to potential ascertainment bias due to increased blood-culturing.
Collapse
Affiliation(s)
- Mark van der Linden
- National Reference Centre for Streptococci, Institute of Medical Microbiology, University Hospital RWTH Aachen, Germany
| | | | | | | | | | | |
Collapse
|
24
|
Arguedas A, Soley C, Abdelnour A. Prevenar experience. Vaccine 2011; 29 Suppl 3:C26-34. [DOI: 10.1016/j.vaccine.2011.06.104] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2011] [Accepted: 06/27/2011] [Indexed: 10/17/2022]
|
25
|
Szynczewska E, Chlebna-Sokół D. Immunogenicity and safety of heptavalent conjugate vaccine against Streptococcus pneumoniae in pre-term Polish infants. Vaccine 2011; 29:7107-13. [PMID: 21803093 DOI: 10.1016/j.vaccine.2011.06.124] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2011] [Revised: 06/21/2011] [Accepted: 06/27/2011] [Indexed: 11/30/2022]
Abstract
The purpose of the study was to assess post-vaccination immune response and occurrence of adverse events in the group of prematurely born infants. The study included 40 pre-term infants. Each child was vaccined four times (2, 4, 6 and 16 months) with the heptavalent conjugated pneumococcal vaccine (PCV7). Assessing of the level of antibodies was performed before vaccination, 4 weeks after primary series, before and 4 weeks after the booster dose. The research participants were qualified into 2 groups: group I - 19 children born before 30th gestational week, group II - 21 children born between the 30th and 34th gestational week. After the basic vaccination, an increase in the average antibody concentration in the area of all serotypes in most of the children tested was registered, with no significant differences observed between the groups. However, differences between individual serotypes were observed. The lowest values were found for serotype 6B. Before administering the booster dose, a significant drop in antibody titre in all of the children tested was noted. The last vaccination caused another significant increase in antibody concentration in both groups and the results obtained were markedly higher than those obtained after administering three vaccine doses. The majority of the children tested (with the exception of three from group II) achieved the preventive antibody level ≥ 0.35 μg/ml. In all of the children, no serious adverse events were observed. Our research showed, that heptavalent pneumococcal conjugate vaccine is immunogenic in children born before the completion of the 34th week of pregnancy. A booster dose of vaccine must be given at the right time to optimal response to the vaccine for all serotypes. Finally, any serious adverse events were observed.
Collapse
Affiliation(s)
- Ewa Szynczewska
- Department of Paediatric Propaedeutics and Metabolic Bone Diseases of Medical University of Lodz, Poland.
| | | |
Collapse
|
26
|
Rodríguez MAG, González AV, Gavín MAO, Martínez FM, Marín NG, Blázquez BR, Moreno JCS. Invasive pneumococcal disease: association between serotype, clinical presentation and lethality. Vaccine 2011; 29:5740-6. [PMID: 21683112 DOI: 10.1016/j.vaccine.2011.05.099] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2011] [Revised: 05/25/2011] [Accepted: 05/27/2011] [Indexed: 11/29/2022]
Abstract
To ascertain the factors linked to invasive pneumococcal disease (IPD) caused by the different serotypes in the period 2007-2009, following the conjugate vaccine's inclusion in the childhood vaccination schedule, a total of 2013 IPD cases were reviewed. The mean annual incidence in this period was 10.74 cases per 100,000 inhabitans and the lethality was 8.8%. Overall serotype distribution displayed certain peculiarities, such as the high frequency of serotype 5. Serotype 3, male gender, sepsis and presence of risk factors were significantly associated with lethality. Vaccinated children under 5 years of age had a higher risk of disease due to serotype 19A. Serotype 8 was associated with the presence of underlying risk factors.
Collapse
Affiliation(s)
- M Angeles Gutiérrez Rodríguez
- Dirección General de Atención Primaria, Subdirección de Promoción de la Salud y Prevención, Consejería de Sanidad, Comunidad de Madrid, Spain.
| | | | | | | | | | | | | |
Collapse
|
27
|
van Mens SP, Meijvis SCA, Endeman H, van Velzen-Blad H, Biesma DH, Grutters JC, Vlaminckx BJM, Rijkers GT. Longitudinal analysis of pneumococcal antibodies during community-acquired pneumonia reveals a much higher involvement of Streptococcus pneumoniae than estimated by conventional methods alone. CLINICAL AND VACCINE IMMUNOLOGY : CVI 2011; 18:796-801. [PMID: 21367978 PMCID: PMC3122512 DOI: 10.1128/cvi.00007-11] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/23/2010] [Accepted: 02/23/2011] [Indexed: 11/20/2022]
Abstract
In up to half of all cases of community-acquired pneumonia (CAP), no pathogen can be identified with conventional diagnostic methods. The most common identified causative agent is Streptococcus pneumoniae. In this study, pneumococcal antibody responses during CAP were analyzed to estimate the contribution of the pneumococcus to all cases of CAP for epidemiological purposes. Pneumococcal antibodies against 14 different serotypes were measured in serum of hospitalized CAP patients. Patients participated in one of two consecutive clinical trials in a general 600-bed teaching hospital in the Netherlands (between October 2004 and June 2009). A significant pneumococcal immune response was defined as at least a 2-fold increase in antibody concentrations against a single serotype between an early (day 1) and a late (day 30) serum sample of each patient with an end concentration above 0.35 μg/ml. A total of 349 adult CAP patients participated in two consecutive clinical trials. For 200 patients, sufficient serum samples were available to determine antibody responses: 62 pneumococcal pneumonia patients, 57 nonpneumococcal pneumonia patients, and 81 patients with an unidentified causative agent. A significant immune response was detected in 45% (28/62 patients) of pneumococcal pneumonia patients, in 5% (3/57) of nonpneumococcal pneumonia patients, and in 28% (23/81) of patients with an unidentified causative agent. The estimated contribution of pneumococci in patients with an unidentified causative agent was calculated to be 57% (95% confidence interval, 36 to 86%). A substantial fraction of pneumococcal pneumonia patients do not elicit a serotype-specific immune response.
Collapse
Affiliation(s)
- Suzan P van Mens
- Department of Medical Microbiology & Immunology, Sint Antonius Hospital, P.O. Box 2500, 3430 EM Nieuwegein, The Netherlands.
| | | | | | | | | | | | | | | |
Collapse
|
28
|
Serotypes of Streptococcus pneumoniae isolates from children with invasive pneumococcal disease in Turkey: baseline evaluation of the introduction of the pneumococcal conjugate vaccine nationwide. CLINICAL AND VACCINE IMMUNOLOGY : CVI 2011; 18:1028-30. [PMID: 21508171 DOI: 10.1128/cvi.00526-10] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Before use of the pneumococcal conjugate vaccine PCV7 became widespread in Turkey, 202 invasive pneumococcus isolates were analyzed. The most common serotypes were 19F and 6B. In children ≤2 years of age, the potential coverage rate of PCV7 was 69.5%. The most frequent non-PCV7 serotypes were 19A, 3, 1, 6A, and 8.
Collapse
|
29
|
McIntosh EDG, Reinert RR. Global prevailing and emerging pediatric pneumococcal serotypes. Expert Rev Vaccines 2011; 10:109-29. [PMID: 21162625 DOI: 10.1586/erv.10.145] [Citation(s) in RCA: 63] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Streptococcus pneumoniae is the leading cause of vaccine-preventable deaths among children younger than 5 years of age worldwide. The 7-valent pneumococcal conjugate vaccine (PCV7) is currently licensed in more than 90 countries and has contributed to significant declines in the incidence of invasive pneumococcal disease (IPD). Recent studies report an increased incidence of IPD caused by non-PCV7 vaccine serotypes (NVTs). Seroepidemiology of IPD caused by NVTs following the introduction of PCV7 is of interest, and this article provides a comprehensive global summary of the prevailing and emerging serotypes causing IPD in children. Currently, globally emerging or persistent NVTs include serotypes 1, 3, 5, 6A, 7F and 19A. Serotypes included in the recently licensed 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PCV10) and 13-valent pneumococcal conjugate vaccine (PCV13) account for pneumococcal disease burdens in most developed countries of 65-85% and 80-90%, respectively. The seroprevalence of NVTs after widespread use of PCV10 and PCV13 requires ongoing monitoring.
Collapse
Affiliation(s)
- E David G McIntosh
- Novartis Vaccines, Hullenbergweg 83-85, Amsterdam 1101CL, The Netherlands.
| | | |
Collapse
|
30
|
Laub R, Baurin S, Timmerman D, Branckaert T, Strengers P. Specific protein content of pools of plasma for fractionation from different sources: impact of frequency of donations. Vox Sang 2011; 99:220-31. [PMID: 20840337 PMCID: PMC3001115 DOI: 10.1111/j.1423-0410.2010.01345.x] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Background and Objectives Plasma pools for the production of human plasma medicinal products are distinguished according to the collection method (recovered or apheresis plasma) and the donor remuneration status. National regulations and the physical status of the donor determine the donation frequency and plasma volume per session. Relevant protein contents of different types of pools have not fully been compared. Materials and Methods We compared the levels of total protein, 15 main relevant plasma protein markers, and anti-B19 and anti-Streptococcus pneumoniae IgG in single-type pools of donations from different countries (Belgium, Finland, France, the Netherlands, Germany, United States). Both recovered plasma from non-remunerated donors and apheresis plasma from remunerated and non-remunerated donors were studied. Results Pools from paid US high-frequency, high-volume plasmapheresis donors showed significantly lower total protein (−9%), albumin (−15%), total IgG (−24%), IgM (−28%), hemopexin (−11%) and retinol-binding protein (−10%) but higher C1-inhibitor, pre-albumin and C-reactive protein contents than pools from unpaid European Union (EU) or US whole-blood or plasmapheresis donors. In contrast to pools from compensated EU plasmapheresis donors, pools from unpaid whole-blood or plasmapheresis donors showed no significant differences, whatever the collection method or country. Reductions in specific protein contents correlated well with protein half-life. Conclusion These results should be taken into account with regard to donor health management and protein recovery.
Collapse
Affiliation(s)
- R Laub
- Central Department for Fractionation, Red Cross, Brussels, Belgium.
| | | | | | | | | |
Collapse
|
31
|
Pneumococcal meningitis: clinical outcomes in a pre-vaccine era at a Dublin paediatric hospital, 1999–2007. Ir J Med Sci 2010; 180:47-50. [DOI: 10.1007/s11845-010-0620-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2009] [Accepted: 10/04/2010] [Indexed: 10/18/2022]
|
32
|
Memish ZA, El-Saed A, Al-Otaibi B, Shaalan MA, Alola SA, Thaqafi AO. Epidemiology of invasive pneumococcal infection in children aged five years and under in Saudi Arabia: a five-year retrospective surveillance study. Int J Infect Dis 2010; 14:e708-12. [PMID: 20627645 DOI: 10.1016/j.ijid.2010.02.2242] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2009] [Revised: 11/16/2009] [Accepted: 02/01/2010] [Indexed: 11/16/2022] Open
Abstract
BACKGROUND The epidemiology of invasive pneumococcal disease (IPD) in children aged <or=5 years in Saudi Arabia has not been described. We conducted a retrospective surveillance study to describe the epidemiology of IPD in the population of children aged <or=5 years served by the National Guard Health Affairs hospitals in central and western regions of Saudi Arabia. METHODS We reviewed the medical records of children <or=5 years old admitted to the King Abdulaziz Medical City hospitals in Riyadh and Jeddah with pneumococcal infections for the period January 1999 through December 2003. Only microbiologically confirmed IPD cases (meningitis or bacteremia) were included in the analysis. RESULTS A total of 82 IPD cases, 19 (23.2%) meningitis and 63 (76.8%) bacteremia, were diagnosed during the five-year period. Of these, 12.2% (10/82) died, with a case-fatality slightly but insignificantly higher in cases of meningitis (15.8%) than bacteremia (11.1%). The average annual IPD incidence was 17.4 per 100,000 (4.0 for meningitis and 13.4 for bacteremia). The incidence was roughly similar in males and females (18.3 and 16.6, respectively; p=0.663) and was almost 4-fold higher in the first year of life compared to the next four years (40.6 and 11.5, respectively; p<0.001). The average annual IPD mortality was 2.1 per 100,000 and was higher in the first year of life compared to the next four years (5.2 and 1.3 , respectively; p=0.043). CONCLUSIONS In the pre-vaccination era (1999-2003) in Saudi Arabia, IPD incidence was comparable to the pre-vaccination incidence rates from many industrialized countries, with children aged <or=1 year suffering the highest IPD risk among those aged <or=5 years.
Collapse
Affiliation(s)
- Ziad A Memish
- Department of Infection Prevention and Control, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
| | | | | | | | | | | |
Collapse
|
33
|
Affiliation(s)
- Ville Peltola
- Department of Pediatrics, Turku University Hospital, and Turku Institute for Child and Youth Research, University of Turku, Turku, Finland.
| |
Collapse
|
34
|
Alexandre C, Dubos F, Courouble C, Pruvost I, Varon E, Martinot A. Rebound in the incidence of pneumococcal meningitis in northern France: effect of serotype replacement. Acta Paediatr 2010; 99:1686-90. [PMID: 20626365 DOI: 10.1111/j.1651-2227.2010.01914.x] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
AIM To determine whether the recent emergence of nonvaccine pneumococcal serotypes has affected the incidence of pneumococcal meningitis in children a few years after the introduction of the heptavalent pneumococcal conjugate vaccine. METHODS We conducted a multicentre retrospective cohort study from 2005 to 2008 in all hospitals with paediatric units in northern France. It included all patients < 18 years of age who were admitted for laboratory-confirmed pneumococcal meningitis during the study period. Data were collected from medical files and laboratory records at each hospital and compared with the regional hospital discharge codes. We assessed global and age-specific incidence rates of pneumococcal meningitis from 2005 through 2008, compared them with those from the prevaccine era (2000-2002) and evaluated pneumococcal serotypes. RESULTS In all, 41 cases were found during the study period. The incidence rate of pneumococcal meningitis varied from 0.8/100,000 children < 18 years in 2005 to 1.8/100,000 children in 2008 (2.2-fold increase, p = 0.06); and from 1.8 to 11.9/100,000 children < 2 years (6.5-fold increase, p = 0.004). This increase was caused by nonvaccine pneumococcal serotypes. CONCLUSION The incidence of pneumococcal meningitis in infants has rebounded in northern France during the pneumococcal conjugate vaccine programme, with the emergence of nonvaccine pneumococcal serotypes.
Collapse
Affiliation(s)
- C Alexandre
- Department of Paediatrics, Paediatric Emergency Unit and Infectious Diseases, Université Lille Nord-de-France, Lille, France
| | | | | | | | | | | |
Collapse
|
35
|
Naturally fluctuating low incidence of invasive pneumococcal infections not affected by large-scale haemophilus influenzae type B vaccination. Pediatr Infect Dis J 2010; 29:777-9. [PMID: 20354461 DOI: 10.1097/inf.0b013e3181dbd820] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
BACKGROUND Since many pathogens colonize the child's oro/nasopharynx in a similar manner, elimination of diseases such as those caused by Haemophilus influenzae type b (Hib) has a potential of augmenting other serious infections. Streptococcus pneumoniae is an agent of special interest now that Hib conjugates have been used widely for more than 2 decades. PATIENTS AND METHODS All blood and cerebrospinal fluid isolations of Hib and S. pneumoniae were collected prospectively from 85,000 Finnish children at age 0-15 years by one central laboratory during 27 years. RESULTS Hib vaccination, launched in 1986-1988, led to a quick decline of cases until the last was detected in 1991. In the next few years, the incidence of bacteremic S. pneumoniae infections increased, but now for 15 years, the numbers of cases have been slowly declining. This finding is not explained by less active sample-taking because the number of blood cultures have almost doubled in the past years. CONCLUSIONS Large-scale Hib vaccination does not increase the incidence of pneumococcal diseases which continue their year-to-year fluctuation at low levels. Only a years-long follow-up permits conclusions on a vaccination's potential influence on the epidemiology of other diseases.
Collapse
|
36
|
Imöhl M, van der Linden M, Mutscher C, Reinert RR. Serotype distribution of invasive pneumococcal disease during the first 60 days of life. Vaccine 2010; 28:4758-62. [DOI: 10.1016/j.vaccine.2010.04.097] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2010] [Revised: 04/06/2010] [Accepted: 04/29/2010] [Indexed: 11/29/2022]
|
37
|
Melo-Cristino J, Santos L, Silva-Costa C, Friães A, Pinho MD, Ramirez M. The Viriato study: update on antimicrobial resistance of microbial pathogens responsible for community-acquired respiratory tract infections in Portugal. Paediatr Drugs 2010; 12 Suppl 1:11-7. [PMID: 20590169 DOI: 10.2165/11538730-s0-000000000-00003] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
The Viriato study is a prospective, multicentre laboratory-based surveillance study of antimicrobial susceptibility in which 30 microbiology laboratories throughout Portugal are asked to isolate, identify and submit to a central laboratory for testing Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis responsible for community-acquired lower respiratory tract infections and Streptococcus pyogenes from tonsillitis. To monitor changes in antimicrobial resistance patterns of these frequent respiratory pathogens. Susceptibility was determined by disk diffusion (Kirby-Bauer) or using Etest strips following the Clinical and Laboratory Standards Institute guidelines. From 1999 to 2007 over 13 900 isolates were analysed. Among S. pneumoniae penicillin non-susceptibility decreased from 25% in 1999 to 18% in 2007 (p = 0.002) but resistance to macrolides showed a steady increase, reaching 20% in the last 6 years. Resistance to amoxicillin and the quinolones remained stable and very low (1-2%) throughout the study period. Antimicrobial resistance among H. influenzae and M. catarrhalis remained stable. The most significant resistance was to ampicillin, of 10-12% and greater than 80%, respectively, as a result of the production of beta-lactamases. Macrolide resistance among S. pyogenes was stable during 1999-2003 (20-23%) but after 2003 there was a steady decline in resistance, which in 2007 reached 10%. The Viriato surveillance study showed that penicillin remains the most active antimicrobial agent against S. pyogenes causing tonsillitis, and amoxicillin-clavulanate and the quinolones are the most active in vitro simultaneously against S. pneumoniae, H. influenzae and M. catarrhalis responsible for community-acquired lower respiratory tract infections in Portugal.
Collapse
Affiliation(s)
- José Melo-Cristino
- Faculty of Medicine, Institute of Microbiology, University of Lisbon, Lisbon, Portugal.
| | | | | | | | | | | | | |
Collapse
|
38
|
Hanquet G, Perrocheau A, Kissling E, Bruhl DL, Tarragó D, Stuart J, Stefanoff P, Heuberger S, Kriz P, Vergison A, de Greeff SC, Amato-Gauci A, Celentano LP. Surveillance of invasive pneumococcal disease in 30 EU countries: Towards a European system? Vaccine 2010; 28:3920-8. [PMID: 20394721 DOI: 10.1016/j.vaccine.2010.03.069] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2009] [Revised: 03/21/2010] [Accepted: 03/26/2010] [Indexed: 11/25/2022]
Abstract
In this era of new pneumococcal conjugate vaccines (PCV), we described and compared surveillance of invasive pneumococcal disease (IPD) and PCV policies in 30 European countries to provide guidance for Europe-wide surveillance. We confirmed the heterogeneity of surveillance systems and case definitions across countries but identified elements common to all countries, such as the availability of serotyping and the surveillance of pneumococcal meningitis. PCV impact was monitored in 11/15 countries using it. We propose steps for the monitoring of incidence rates and serotype distribution at EU level, to assess the need to introduce PCV and monitor its impact once introduced.
Collapse
|
39
|
Trotter CL, Waight P, Andrews NJ, Slack M, Efstratiou A, George R, Miller E. Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: England and Wales, 1996–2006. J Infect 2010; 60:200-8. [DOI: 10.1016/j.jinf.2009.12.008] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2009] [Revised: 12/14/2009] [Accepted: 12/15/2009] [Indexed: 10/20/2022]
|
40
|
Association of serotypes of Streptococcus pneumoniae with age in invasive pneumococcal disease. J Clin Microbiol 2010; 48:1291-6. [PMID: 20107087 DOI: 10.1128/jcm.01937-09] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
A total of 7,764 isolates from patients with invasive pneumococcal disease (IPD) were collected from 1992 to June 2006. Data on serotypes were available for 5,022 isolates (64.7% of all invasive isolates). Some 54.0% of the isolates originated from adults >or=16 years of age, and 46.0% were from children <16 years of age. The leading serotypes were 14, 23F, 1, 6B, 7F, 3, and 4. The serotypes significantly more common in children were 14, 6B, 19F, and 18C, while among adults, serotypes 3 and 4 were predominant. Serotype 7F was statistically more prevalent among children <4 months old than among the other age groups. Among children aged >or=4 months and <1 year, serotype 19F occurred statistically more frequently; and among children aged >or=1 year to <5 years, serotypes 14, 6B, and 18C were overrepresented. The serotypes predominantly affecting patients younger than the remaining collective of patients were 14, 6B, 19F, and 18C, while patients with IPD caused by serotypes 3, 4, and 9V were older than the collective, on average.
Collapse
|
41
|
Milne RJ, Vander Hoorn S. Burden and cost of hospital admissions for vaccine-preventable paediatric pneumococcal disease and non-typable Haemophilus influenzae otitis media in New Zealand. APPLIED HEALTH ECONOMICS AND HEALTH POLICY 2010; 8:281-300. [PMID: 20804222 DOI: 10.2165/11535710-000000000-00000] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
INTRODUCTION Streptococcus pneumoniae (Sp.) is a leading cause of paediatric bacterial meningitis, pneumonia and acute otitis media, as is non-typable Haemophilus influenzae (NTHi) for acute otitis media. In 2008, a 7-valent conjugated pneumococcal vaccine (PCV7) was included in the New Zealand (NZ) childhood immunization schedule. OBJECTIVE To estimate the potentially vaccine-preventable annual hospital admissions and cost to the NZ Government of paediatric admissions for pneumococcal disease and NTHi otitis media prior to the immunization programme. METHODS Admissions (2000-7) and deaths (2000-5) in children aged<20 years with pneumococcal meningitis or bacteraemia, pneumonia or otitis media were identified in national datasets and linked by unique patient identifiers. New episodes of illness were defined as admissions occurring >30 days after discharge from a previous admission. Informed by the literature, pneumococcal pneumonia episodes were estimated at 33% of all-cause pneumonia admissions; Sp. and NTHi otitis media episodes were estimated jointly at 72% of otitis media admissions. Each episode was assigned a single diagnosis according to the following hierarchy: meningitis>bacteraemia>pneumonia>otitis media. Incidence rates for episodes were determined for 2000-7 (meningitis, bacteraemia and pneumonia) and 2006-7 (otitis media). Annual DRG-based costs for pneumococcal meningitis, bacteraemia, pneumonia and otitis media were estimated as (episode rate)x(DRG cost weight per episode)x(2007 population)x(national price per cost weight). RESULTS Episode rates for pneumococcal meningitis, bacteraemia and pneumonia were stable in 2000-7, highest in the second 6 months of life and declined steeply over the first 5 years of life. Mean rates per 100000 in 2000-7 were 18.4, 27.6 and 464 for pneumococcal meningitis, bacteraemia and pneumonia, respectively, for children aged<2 years; 8.4, 14.9 and 295 for children aged<5 years (including those aged<2 years); and 2.2, 4.4 and 97 for children aged<20 years (including those aged<5 years). Mean rates per 100000 in 2006-7 for Sp. and NTHi otitis media combined were 631 (surgical) and 197 (medical) for children aged<2 years; 691 and 116 for children aged<5 years; and 281 and 35 for children aged<20 years. Pacific Island and indigenous Māori children generally had higher rates than European/other children. Rates increased with socioeconomic disadvantage, across all diagnoses. The annual cost to Government of pneumococcal disease and NTHi otitis media admissions for children aged<20 years was estimated at New Zealand dollars ($NZ)9.95 million (range 7.7-12.2 million) [about $US7.1 million]. Most of this cost was shared between pneumococcal pneumonia (48%) and otitis media (45%), and 78% was incurred in the first 2 years of life. Estimated annual paediatric mortality rates per 100 000 for children aged<5 years were 0.48, 0.30 and 0.54 for pneumococcal meningitis, bacteraemia and pneumonia, respectively. The analysis predicted four or five pneumococcal deaths per year (range 1-8) for children aged<5 years. CONCLUSIONS Prior to the introduction of a national Sp. immunization programme, hospital admissions for Sp. disease and NTHi otitis media in NZ cost about $NZ10 million annually, mostly for children aged<2 years and particularly for those living in relative socioeconomic deprivation and for Pacific Island and Māori children. There were about five pneumococcal deaths annually. With adjustment for local serotypes, vaccine serotype coverage and uptake, immunization with any of the three available pneumococcal vaccines would reduce this burden substantially.
Collapse
Affiliation(s)
- Richard J Milne
- School of Population Health, Department of Statistics, University of Auckland, Auckland, New Zealand.
| | | |
Collapse
|
42
|
Immunization with a combination of three pneumococcal proteins confers additive and broad protection against Streptococcus pneumoniae Infections in Mice. Infect Immun 2009; 78:1276-83. [PMID: 20038538 DOI: 10.1128/iai.00473-09] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Pneumococcal polysaccharide-based vaccines are effective in preventing pneumococcus infection; however, some drawbacks preclude their widespread use in developing and undeveloped countries. Here, we evaluated the protective effects of ATP-dependent caseinolytic protease (ClpP), pneumolysin mutant (DeltaA146 Ply), putative lipoate-protein ligase (Lpl), or combinations thereof against pneumococcal infections in mice. Vaccinated mice were intraperitoneally and/or intranasally challenged with different pneumococcal strains. In intraperitoneal challenge models with pneumococcal strain D39 (serotype 2), the most striking protection was obtained with the combination of the three antigens. Similarly, with the intranasal challenge models, (i) additive clearance of bacteria in lungs was observed for the combination of the three antigens and (ii) a combination vaccine conferred complete protection against intranasal infections of three of the four most common pneumococcal strains (serotypes 14, 19F, and 23F) and 80% protection for pneumococcal strain 6B. Even so, immunity to this combination could confer protection against pneumococcal infection with a mixture of four serotypes. Our results showed that the combination vaccine was as effective as the currently used vaccines (PCV7 and PPV23). These results indicate that system immunization with the combination of pneumococcal antigens could provide an additive and broad protection against Streptococcus pneumoniae in pneumonia and sepsis infection models.
Collapse
|
43
|
Guevara M, Barricarte A, Gil-Setas A, García-Irure JJ, Beristain X, Torroba L, Petit A, Polo Vigas ME, Aguinaga A, Castilla J. Changing epidemiology of invasive pneumococcal disease following increased coverage with the heptavalent conjugate vaccine in Navarre, Spain. Clin Microbiol Infect 2009; 15:1013-9. [PMID: 19673968 DOI: 10.1111/j.1469-0691.2009.02904.x] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
The present study evaluated changes in the incidence of invasive pneumococcal disease (IPD) and the pattern of serotypes isolated in Navarre, Spain, after the introduction and increased coverage of the heptavalent pneumococcal conjugate vaccine (PCV7). All cases with isolation of pneumococcus from normally sterile bodily fluids were included. The incidence of IPD in children and adults was compared for the periods 2001-2002 and 2006-2007. By the end of 2002, only 11% of children aged <5 years had received any dose of PCV7, whereas, beginning in 2007, the proportion exceeded 50%. Among the cases of IPD aged <5 years, the percentage of those vaccinated increased from 7% during 2001-2002 to 53% during 2006-2007 (p <0.001). The incidence of IPD from PCV7-serotypes decreased by 85% in children <5 years (p <0.001), by 45% in the population aged 5-64 years (p 0.10) and by 68% in those >or=65 years (p 0.004). By contrast, the incidence of IPD from non-PCV7 serotypes increased by 40% overall (p 0.006). The incidence of IPD from all serotypes did not change significantly in children <5 years (from 83 to 72 per 100 000) or in the total population (from 15.8 to 16.3 per 100 000). The percentage of cases as a result of serotypes 7 and 19A increased significantly in both children and adults. No significant changes were seen in the clinical forms of IPD. The pattern of serotypes causing IPD has changed, in both children and adults, following the increased coverage of PCV7, although the incidence has been reduced only slightly.
Collapse
Affiliation(s)
- M Guevara
- Instituto de Salud Pública de Navarra, Navarre, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
|
45
|
Levy C, de La Rocque F, Cohen R. Actualisation de l’épidémiologie des méningites bactériennes de l’enfant en France. Med Mal Infect 2009; 39:419-31. [DOI: 10.1016/j.medmal.2009.03.006] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2009] [Accepted: 02/20/2009] [Indexed: 10/20/2022]
|
46
|
Haas H. Antibiothérapie d’une méningite présumée bactérienne de l’enfant (rationnel, modalités, durée, suivi). Med Mal Infect 2009; 39:647-58. [DOI: 10.1016/j.medmal.2009.02.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2009] [Accepted: 02/20/2009] [Indexed: 10/20/2022]
|
47
|
Romney MG, Hull MW, Gustafson R, Sandhu J, Champagne S, Wong T, Nematallah A, Forsting S, Daly P. Large community outbreak of Streptococcus pneumoniae serotype 5 invasive infection in an impoverished, urban population. Clin Infect Dis 2009; 47:768-74. [PMID: 18690803 DOI: 10.1086/591128] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
BACKGROUND Streptococcus pneumoniae is a common cause of sporadic invasive infections, but outbreaks of invasive pneumococcal disease are infrequent. In August 2006, a sudden increase in the number of patients presenting with invasive pneumococcal disease was noted at St. Paul's Hospital (Vancouver, Canada). Most patients with severe disease resided in an area referred to as the Downtown Eastside, a neighborhood known for its high rates of poverty and illicit drug use. METHODS Prospective, laboratory-based surveillance for invasive pneumococcal disease was initiated, including on-site serotyping of S. pneumoniae isolates. A vaccination campaign using 23-valent polysaccharide pneumococcal vaccine was launched in the Downtown Eastside. Multiple logistic regression was used to examine the association of sociodemographic variables and medical risk factors with S. pneumoniae serotype status. RESULTS A single S. pneumoniae serotype (serotype 5) was responsible for 78% of invasive pneumococcal disease cases (137 of 175 cases) during the outbreak period of August 2006-July 2007. The outbreak strain, although fully susceptible to penicillin, caused significant morbidity and placed considerable strain on the acute care system within the Vancouver Coastal Health region. Crack cocaine use was found to be the main independent risk factor associated with invasive pneumococcal disease due to S. pneumoniae serotype 5 (odds ratio, 12.4; 95% confidence interval, 2.22-69.5). CONCLUSIONS A targeted vaccination campaign using polysaccharide pneumococcal vaccine appeared to help control this outbreak. In urban centers with high rates of illicit drug use, vaccination strategies for preventing invasive pneumococcal disease may need to be refined to include individuals who use crack cocaine.
Collapse
Affiliation(s)
- Marc G Romney
- Department of Pathology, Laboratory Medicine, St Paul's Hospital, Providence Health Care, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
| | | | | | | | | | | | | | | | | |
Collapse
|
48
|
National paediatric immunization program of high risk groups: no effect on the incidence of invasive pneumococcal diseases. Vaccine 2009; 27:3963-8. [PMID: 19393711 DOI: 10.1016/j.vaccine.2009.04.044] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2008] [Revised: 04/08/2009] [Accepted: 04/15/2009] [Indexed: 11/22/2022]
Abstract
This study monitors the epidemiology of invasive pneumococcal diseases (IPD) in hospitalized children up to 60 months of age before (February 2001-October 2004) and after (November 2004-January 2007) the introduction of a national risk group immunization program with "Prevenar" in Austria. The IPD incidence rates, per 100,000, for IPD were 7.6 before and 6.4 after the risk group immunization program, while there was a significant reduction (p<0.05) for meningitis, 3.1 before and 1.6 after. Overall, the most commonly observed serotypes were 14 (34.2%), 6B (11.7%), and 23F (6.7%). 71.7% of the identified strains were vaccine types; 12.5% were vaccine-related serotypes. No clinically relevant changes in the incidence rate of IPDs or shift/replacement of serotypes was documented. Antimicrobial resistance predominated against erythromycin (32.5%) and clarithromycin (26.7%). Our data show that this risk group vaccination program had no impact on the incidence of IPD in young children.
Collapse
|
49
|
Epidemiology of pneumococcal meningitis hospitalizations in pediatric population in Spain (1998–2006). Vaccine 2009; 27:2669-73. [DOI: 10.1016/j.vaccine.2009.02.063] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2008] [Revised: 11/27/2008] [Accepted: 02/18/2009] [Indexed: 11/22/2022]
|
50
|
Invasive pneumococcal disease in the Netherlands: Syndromes, outcome and potential vaccine benefits. Vaccine 2009; 27:2394-401. [DOI: 10.1016/j.vaccine.2009.01.127] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2008] [Revised: 01/28/2009] [Accepted: 01/29/2009] [Indexed: 11/18/2022]
|